June 28, 2002 — Nanogen Inc. said it has shipped evaluation samples of a reagent designed to detect gene mutations linked to cystic fibrosis.
Nanogen’s cystic fibrosis analyte specific reagents offer an automated method to detect the 25 mutations most commonly associated with the disorder. The tests can be performed on the company’s NanoChip Molecular Biology Workstation, which Nanogen said is the first microarray capable of analyzing the cystic fibrosis gene.
Additional customer evaluations are scheduled before commercial release, the company said in a news release.